Gil Dan Rabinovici

Large-scale cerebrospinal fluid proteomics identifies diagnostic biomarker candidates across the clinico-pathological continuum of frontotemporal lobar degeneration

The paper identifies potential diagnostic biomarkers for frontotemporal lobar degeneration subtypes using cerebrospinal fluid proteomics.

Cerebrospinal fluid YWHAG:NPTX2 ratio predicts clinical severity and future phenoconversion in frontotemporal lobar degeneration

The paper identifies the CSF YWHAG:NPTX2 ratio as a biomarker for predicting clinical severity and phenoconversion in FTLD, showing strong correlation with disease progression and improved trial design potential.

Characterisation of Posterior Predominant Amyloid PET Binding Across Multiple Cohorts

This paper identifies a posterior predominant amyloid PET binding pattern in multiple cohorts, showing its clinical and biological relevance and suggesting the need for more nuanced analysis methods.

Functional network collapse in neurodegenerative disease

This study identifies functional network changes in neurodegenerative diseases using MRI data, linking brain atrophy to specific connectivity patterns and cognitive deficits.

Interrogating the plasma proteome of repetitive head impact exposure and chronic traumatic encephalopathy

This study identifies plasma proteomic signatures associated with repetitive head impact exposure and CTE, linking them to immune, mitochondrial, and metabolic pathways and cognitive decline.

Imaging synaptic density in ageing and Alzheimer's Disease with -SynVesT-1

This study uses [18F]-SynVesT-1 PET to analyze synaptic density in aging and Alzheimer's Disease, finding associations with amyloid-beta, tau, and cognitive performance.

Expansion of highly interferon-responsive T cells in early-onset Alzheimer's disease

The paper identifies an expansion of interferon-responsive T cells in early-onset Alzheimer's disease using single-cell RNA-sequencing and ddPCR data.

Neurophysiological trajectories in Alzheimer's disease progression

This study uses event-based sequencing models to analyze neural oscillation trajectories in Alzheimer's disease stages, finding frequency-specific synchrony changes linked to early neurodegeneration and cognitive decline.

Altered excitatory and inhibitory neuronal subpopulation parameters are distinctly associated with tau and amyloid in Alzheimer's disease

The paper examines associations between neuronal subpopulation parameters and tau/A{beta} in AD patients using MEG and PET data.

Data-driven detection of latent atrophy factors related to phenotypical variants of posterior cortical atrophy

The paper identifies four latent atrophy factors in posterior cortical atrophy using Bayesian modeling, finding that most patients exhibit mixed profiles rather than distinct variants.

Non-Coding and Loss-of-Function Coding Variants in TET2 are Associated with Multiple Neurodegenerative Diseases

The paper identifies rare variants in TET2 associated with early-onset Alzheimer's disease and frontotemporal dementia, highlighting both coding and non-coding variants as risk factors.

A molecular gradient along the longitudinal axis of the human hippocampus informs large-scale behavioral systems

The paper identifies a molecular gradient along the human hippocampus's longitudinal axis that correlates with distinct brain systems and behavioral functions.

Lipid associated polygenic enrichment in Alzheimer’s disease

The paper identifies genetic variants associated with Alzheimer's disease and cardiovascular risk factors, showing lipid-related enrichment and pleiotropy beyond APOE.

Immune-related genetic enrichment in frontotemporal dementia

This study identifies genetic overlaps between frontotemporal dementia and immune-mediated diseases, finding strong enrichment with rheumatoid arthritis and moderate enrichment with other immune conditions.

Polygenic hazard score: an enrichment marker for Alzheimer’s associated amyloid and tau deposition

This study evaluates whether a polygenic hazard score (PHS) can enhance the prediction of amyloid and tau deposition and progression to Alzheimer’s dementia when combined with biomarkers in nondemented individuals.